Kane William P Jr 4

What Happened

• Director William P. Kane Jr. received a derivative award (an option covering 10,000 shares) from LB Pharmaceuticals (LBRX) on June 3, 2026. The reported acquisition price is $0.00, so no cash was paid at grant; this is a compensation award, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-03; Filing date: 2026-06-05 (appears timely).
• Instrument: Derivative award (option) covering 10,000 shares; reported price per share: $0.00.
• Reported value: $0 at grant per SEC entry (compensation value may be disclosed elsewhere in proxy or grant agreements).
• Shares owned after transaction: Not specified in the supplied filing details.
• Footnote: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of stockholders, subject to the reporting person’s continuous service through such vesting date.

Context

• This is a forward-looking compensation grant (an option) that vests over time; it is not an immediate sale or cash exercise. Such grants are common for directors as part of compensation and do not by themselves indicate a buy or sell signal.